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 Thyroid disorders are more common in diabetic patients than in the general population. Abnormal thyroid function 
can be found in as many as 11% to 30% of patients with diabetes mellitus (DM) type 1 or 2. Thus, the Polish 
Society of Endocrinology and Polish Diabetes Association recommends screening for thyroid dysfunction in all 
patients with DM. According to these recommendations, concentrations of thyrotropin (TSH) and thyroid 
peroxidase antibodies (TPOAb) should be measured in every patient with newly diagnosed DM1, and in all 
patients with DM1 who have never undergone thyroid function tests. In exactly the same situations, patients with 
DM2 require TSH assessment, while TPOAb titer should be measured only if TSH reaches ≥ 2.0 mIU/L. In 
diabetic patients with TSH concentration ≥ 2.0 mIU/L and elevated TPOAb level, free thyroxin level should be 
assessed and – if normal – subsequently TSH should be monitored once a year. If the TSH concentration ≥ 2.0 
mIU/L co-occurs with TPOAb titer within the reference range, TSH assessment should be repeated every other 
year. Patients with TSH < 2.0 mIU/L and normal TPOAb titer should undergo TSH testing every five years. 
Diabetic patients with a family history of chronic autoimmune thyroiditis require TSH testing once a year. If 
TPOAb titer is elevated in patients with DM2, the type of DM should be reassessed by measuring the level of 
antibodies against glutamic acid decarboxylase. 
Special attention should be paid to women who are pregnant or planning pregnancy. In the preconception period, 
TSH concentration should be measured in every woman with DM, and in DM1 patients together with TPOAb 
level. When pregnancy is confirmed, assessment of TSH and TPOAb is advised at the first obstetrician 
appointment (before 9
th
 week of pregnancy). In all pregnant diabetic patients with a past medical history of Graves’ 
disease, anti-TSH receptor antibodies (TRAb) should be additionally measured at the first obstetrician appointment 
and repeated at the end of the second trimester (before the 22
nd
 week of pregnancy). 
If carbohydrate balance is unimpaired, hyperthyroidism is rarely accompanied by hyperglycemia. Abnormal fasting 
or postprandial glucose levels in patients with hyperthyroidism indicate increased risk of developing diabetes. In 
such patients, oral glucose tolerance test (OGTT) should be performed once the euthyroidism is achieved. In 
diabetic patients, hyperthyroidism causes deterioration of metabolic control of DM and leads to all the systemic 
consequences of hyperglycemia, including increased risk of ketoacidosis. Additionally, even slight thyroid 
hormone excess significantly increases the risk of cardiovascular disease in patients with DM. Thus, both overt and 
subclinical hyperthyroidism should be treated in this group of patients. In diabetic patients with thyroid 
orbitopathy, the risk of optic neuropathy is increased, and intensive anti-inflammatory treatment should be 
introduced in every active disease except for the mild course cases. On the other hand, administering high steroid 
doses in patients with DM adversely influences the metabolic control of diabetes. Hence, in patients treated with 
oral anti-diabetic medications, periodic insulin therapy should be introduced along with steroid administration. 
In diabetic patients, also the hypothyroidism is proven to be an independent risk factor for cardiovascular episodes. 
Therefore, treatment of subclinical hypothyroidism is strongly recommended in this condition. 
Hypoglycemia or reduced insulin requirement in diabetic patients may indicate concomitant development of 
hypothyroidism and/ or – especially in patients with DM1 – adrenal insufficiency and polyglandular autoimmune 
syndrome. Unexplained hypoglycemic states always require hormonal testing to exclude these endocrine disorders. 
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